ACLY and autoimmune polyendocrinopathy: Defining the threshold between low (i.e., clinically less significant) and medium-high (clinically more significant) aCL and β2GPI antibody levels helps distinguish APS patients from other diseases, but may lead to inappropriate decisions if interpreted improperly.